A
Alfonso Tafur
Researcher at NorthShore University HealthSystem
Publications - 147
Citations - 5501
Alfonso Tafur is an academic researcher from NorthShore University HealthSystem. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 25, co-authored 131 publications receiving 3584 citations. Previous affiliations of Alfonso Tafur include Cardiovascular Institute of the South & University of Oklahoma Health Sciences Center.
Papers
More filters
Journal ArticleDOI
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up
Behnood Bikdeli,Mahesh V. Madhavan,David Jiménez,Taylor Chuich,Isaac Dreyfus,Elissa Driggin,Caroline Der Nigoghossian,Walter Ageno,Mohammad Madjid,Yutao Guo,Liang V. Tang,Yu Hu,Jay Giri,Mary Cushman,Isabelle Quéré,Evangelos Dimakakos,C. Michael Gibson,C. Michael Gibson,Giuseppe Lippi,Emmanuel J. Favaloro,Jawed Fareed,Joseph A. Caprini,Alfonso Tafur,John R. Burton,Dominic P. Francese,Elizabeth Y. Wang,Anna Falanga,Claire McLintock,Beverley J. Hunt,Alex C. Spyropoulos,Geoffrey D. Barnes,John W. Eikelboom,John W. Eikelboom,Ido Weinberg,Sam Schulman,Marc Carrier,Gregory Piazza,Gregory Piazza,Joshua A. Beckman,P. Gabriel Steg,Gregg W. Stone,Stephan Rosenkranz,Samuel Z. Goldhaber,Samuel Z. Goldhaber,Sahil A. Parikh,Manuel Monreal,Harlan M. Krumholz,Stavros Konstantinides,Jeffrey I. Weitz,Gregory Y.H. Lip,Gregory Y.H. Lip +50 more
TL;DR: The current understanding of the pathogenesis, epidemiology, management and outcomes of patients with COVID-19 who develop venous or arterial thrombosis, and of those with preexistingThrombotic disease who develop CO VID-19 are reviewed.
Journal ArticleDOI
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial.
Robert D. McBane,Waldemar E. Wysokinski,Jennifer Le-Rademacher,Tyler Zemla,Aneel A. Ashrani,Alfonso Tafur,Usha Perepu,Daniel M. Anderson,Krishna Gundabolu,Charles Kuzma,Juliana Perez Botero,Roberto A. Leon Ferre,Stanislav Henkin,Charles J. Lenz,Damon E. Houghton,Prakash Vishnu,Charles L. Loprinzi +16 more
TL;DR: Low‐molecular‐weight heparin is the guideline‐endorsed treatment for cancer‐associated venous thromboembolism (VTE) and apixaban is approved for the treatment of acute VTE.
Journal ArticleDOI
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
Alex C. Spyropoulos,Alex C. Spyropoulos,Alex C. Spyropoulos,Mark Goldin,Mark Goldin,Dimitrios Giannis,Wassim Diab,Janice Wang,Janice Wang,Sameer Khanijo,Andrea Mignatti,Andrea Mignatti,Eugenia Gianos,Eugenia Gianos,Marc Cohen,Gulru Sharifova,Jeet Lund,Alfonso Tafur,Alfonso Tafur,Paul A. Lewis,Kevin P. Cohoon,Husneara Rahman,Cristina Sison,Cristina Sison,Martin Lesser,Martin Lesser,Kanta Ochani,Nirav Agrawal,Judith Hsia,Victoria E. Anderson,Marc P. Bonaca,Jonathan L. Halperin,Jeffrey I. Weitz,Hep-Covid Investigators +33 more
TL;DR: In this article, the authors evaluated the effects of therapeutic-dose low-molecular-weight heparin (LMWH) vs institutional standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19.
Journal ArticleDOI
Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant
James D. Douketis,Alex C. Spyropoulos,Joanne Duncan,Marc Carrier,Grégoire Le Gal,Alfonso Tafur,Thomas Vanassche,Peter Verhamme,Sudeep Shivakumar,Peter L. Gross,Agnes Y.Y. Lee,Erik Yeo,Susan Solymoss,Jeannine Kassis,Geneviève Le Templier,Stephen Kowalski,Mark Blostein,Vinay Shah,Elizabeth MacKay,Cynthia Wu,Nathan P. Clark,Shannon M. Bates,Frederick A. Spencer,Eleni Arnaoutoglou,Michiel Coppens,Donald M. Arnold,Joseph A. Caprini,Na Li,Karen A. Moffat,Summer Syed,Sam Schulman +30 more
TL;DR: Patients with atrial fibrillation who had DOAC therapy interruption for elective surgery or procedure, a perioperative management strategy without heparin bridging or coagulation function testing was associated with low rates of major bleeding and arterial thromboembolism.
Journal ArticleDOI
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.
Behnood Bikdeli,Behnood Bikdeli,Mahesh V. Madhavan,Aakriti Gupta,Aakriti Gupta,David Jiménez,John R. Burton,Caroline Der Nigoghossian,Taylor Chuich,Shayan Nabavi Nouri,Isaac Dreyfus,Elissa Driggin,Sanjum S. Sethi,Kartik Sehgal,Kartik Sehgal,Saurav Chatterjee,Walter Ageno,Mohammad Madjid,Yutao Guo,Yutao Guo,Liang V. Tang,Yu Hu,Laurent Bertoletti,Jay Giri,Jay Giri,Jay Giri,Mary Cushman,Isabelle Quéré,Evangelos Dimakakos,C. Michael Gibson,C. Michael Gibson,Giuseppe Lippi,Emmanuel J. Favaloro,Jawed Fareed,Alfonso Tafur,Alfonso Tafur,Dominic P. Francese,Jaya Batra,Anna Falanga,Kevin J. Clerkin,Nir Uriel,Ajay J. Kirtane,Claire McLintock,Beverley J. Hunt,Alex C. Spyropoulos,Geoffrey D. Barnes,John W. Eikelboom,Ido Weinberg,Sam Schulman,Sam Schulman,Marc Carrier,Gregory Piazza,Gregory Piazza,Joshua A. Beckman,Martin B. Leon,Gregg W. Stone,Stephan Rosenkranz,Samuel Z. Goldhaber,Samuel Z. Goldhaber,Sahil A. Parikh,Manuel Monreal,Harlan M. Krumholz,Stavros Konstantinides,Jeffrey I. Weitz,Gregory Y.H. Lip,Gregory Y.H. Lip +65 more
TL;DR: Novel dosing approaches are described for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithsombotic drugs in the absence of confirmed thrombosis.